MXPA04000541A - Formulacion liofilizada de 2-metil-tieno-benzodiazepina. - Google Patents

Formulacion liofilizada de 2-metil-tieno-benzodiazepina.

Info

Publication number
MXPA04000541A
MXPA04000541A MXPA04000541A MXPA04000541A MXPA04000541A MX PA04000541 A MXPA04000541 A MX PA04000541A MX PA04000541 A MXPA04000541 A MX PA04000541A MX PA04000541 A MXPA04000541 A MX PA04000541A MX PA04000541 A MXPA04000541 A MX PA04000541A
Authority
MX
Mexico
Prior art keywords
olanzapine
lyophilized formulation
lyophilized
formulation
amorphous
Prior art date
Application number
MXPA04000541A
Other languages
English (en)
Spanish (es)
Inventor
Douglas Dekemper Kurt
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA04000541A publication Critical patent/MXPA04000541A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MXPA04000541A 2001-07-20 2002-07-05 Formulacion liofilizada de 2-metil-tieno-benzodiazepina. MXPA04000541A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US38647402P 2002-06-07 2002-06-07
PCT/US2002/019799 WO2003007912A2 (en) 2001-07-20 2002-07-05 Lyophilized formulation comprising olanzapine

Publications (1)

Publication Number Publication Date
MXPA04000541A true MXPA04000541A (es) 2004-05-04

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000541A MXPA04000541A (es) 2001-07-20 2002-07-05 Formulacion liofilizada de 2-metil-tieno-benzodiazepina.

Country Status (32)

Country Link
US (1) US20040176357A1 (enExample)
EP (1) EP1423124B1 (enExample)
JP (1) JP2004537546A (enExample)
KR (1) KR20040017330A (enExample)
CN (1) CN1537007A (enExample)
AR (1) AR036180A1 (enExample)
AT (1) ATE369137T1 (enExample)
AU (1) AU2002320134B2 (enExample)
BR (1) BR0211250A (enExample)
CA (1) CA2448724A1 (enExample)
CO (1) CO5540279A2 (enExample)
CY (1) CY1107759T1 (enExample)
CZ (1) CZ200484A3 (enExample)
DE (1) DE60221674T2 (enExample)
DK (1) DK1423124T3 (enExample)
EA (1) EA006506B1 (enExample)
ES (1) ES2289126T3 (enExample)
HR (1) HRP20040037A2 (enExample)
HU (1) HUP0401157A3 (enExample)
IL (1) IL159098A0 (enExample)
MX (1) MXPA04000541A (enExample)
MY (1) MY135452A (enExample)
NZ (1) NZ529667A (enExample)
PE (1) PE20030281A1 (enExample)
PL (1) PL366614A1 (enExample)
PT (1) PT1423124E (enExample)
SI (1) SI1423124T1 (enExample)
SK (1) SK182004A3 (enExample)
SV (1) SV2003001179A (enExample)
UA (1) UA80095C2 (enExample)
WO (1) WO2003007912A2 (enExample)
ZA (1) ZA200400798B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
AU2019205329B2 (en) * 2018-01-05 2023-04-20 Impel Pharmaceuticals Inc. Intranasal delivery of olanzapine by precision olfactory device
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69004921T2 (de) * 1989-09-30 1994-05-05 Eisai Co Ltd Injizierbare Cephalosporinpräparate und ihre Anwendung.
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
KR20040017330A (ko) 2004-02-26
IL159098A0 (en) 2004-05-12
CA2448724A1 (en) 2003-01-30
SK182004A3 (en) 2004-09-08
CN1537007A (zh) 2004-10-13
HK1066484A1 (en) 2005-03-24
NZ529667A (en) 2006-02-24
DE60221674T2 (de) 2008-04-30
WO2003007912A3 (en) 2003-05-01
MY135452A (en) 2008-04-30
SV2003001179A (es) 2003-07-29
CO5540279A2 (es) 2005-07-29
HUP0401157A3 (en) 2008-01-28
EA200400211A1 (ru) 2004-06-24
EP1423124A2 (en) 2004-06-02
HRP20040037A2 (en) 2004-06-30
BR0211250A (pt) 2004-07-27
PE20030281A1 (es) 2003-03-27
US20040176357A1 (en) 2004-09-09
WO2003007912A2 (en) 2003-01-30
EA006506B1 (ru) 2005-12-29
JP2004537546A (ja) 2004-12-16
HUP0401157A2 (hu) 2004-10-28
PL366614A1 (en) 2005-02-07
SI1423124T1 (sl) 2008-02-29
ATE369137T1 (de) 2007-08-15
UA80095C2 (en) 2007-08-27
DE60221674D1 (de) 2007-09-20
AU2002320134B2 (en) 2007-04-05
AR036180A1 (es) 2004-08-18
CZ200484A3 (cs) 2005-01-12
CY1107759T1 (el) 2013-06-19
EP1423124B1 (en) 2007-08-08
PT1423124E (pt) 2007-10-29
ZA200400798B (en) 2005-07-27
ES2289126T3 (es) 2008-02-01
DK1423124T3 (da) 2007-12-03

Similar Documents

Publication Publication Date Title
ZA200306806B (en) Preparation for the prophylaxis of restenosis.
ZA200307646B (en) Benzamidine derivative.
WO2003023178A3 (en) Adjustable expansion cone assembly
AU2002258913A1 (en) Bifunctional-modified hydrogels
CY1107759T1 (el) Λυοφιλισμενη συνταγοποιηση που περιλαμβανει ολανζαπινη
ZA200208561B (en) Hydraulischer druckverstarker.
MXPA01009037A (es) I-bet.
AU148078S (en) Bottle
MXPA03005286A (es) METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
MXPA03008139A (es) Fluoralcoxifenilsulfonilureas sustituidas.
AU2002304853A1 (en) Substituted benzopyranones as telomerase inhibitors
ZA200206779B (en) Solid formulation.
AU148415S (en) Bottle
AU2002222891A1 (en) High dynamic range receiver
AU2001293214A1 (en) Heatsink retainer
AU2002213505A1 (en) Process for the preparation of pgd2 antagonist
ECSP044949A (es) Formulacion liofilizada de 2-metil-tieno-benzodiazepina
ZA200201497B (en) An ashtray.
AU3315302A (en) Point contacts for semiconductors and the production thereof
ZA200208145B (en) An insulating component.
JO2151B1 (en) Toilet (T.S)
GB0112068D0 (en) Greensnail . com
AU2002321921A1 (en) Light-emitting fluorene-based copolymers, el devices comprising the same and method of synthesis thereof.
AU2001269068A1 (en) Disubstituted 7,9-guaninium halides as telomerase inhibitors
AU2002344760A1 (en) Low profile, high stretch knit prosthetic device

Legal Events

Date Code Title Description
FG Grant or registration